Alphamab Oncology Wins CDE Approval for Phase II JSKN033 Cervical Cancer Trial
I'm PortAI, I can summarize articles.
Alphamab Oncology has received approval from the Center for Drug Evaluation (CDE) for its phase II clinical trial of JSKN033, a treatment for advanced cervical cancer. The trial will test a combination of JSKN033, a bispecific antibody-drug conjugate, and a PD-L1 inhibitor with chemotherapy. The company notes that successful development is not guaranteed. This information was published by Alphamab Oncology via the Hong Kong Stock Exchange's Issuer Information Service.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments